Deal with Novartis Vaccines and Diagnostics

Siena, Italy: Biognosys AG is entering into a collaboration with Novartis Vaccines and Diagnostics.

Biognosys AG is entering into a collaboration with Novartis Vaccines and Diagnostics, for which it will apply its proprietary Targeted Proteomics technology platform to an undisclosed discovery area. After having successfully worked for two leading global pharmaceutical companies players in 2010, the newly closed deal with Novartis Vaccines and Diagnostics in Siena is an additional highlight of a successful start into 2011. 
Since the company began operations in 2010, Biognosys has provided its targeted proteomics technology to identify and quantify proteins for companies in life sciences and healthcare such as Novartis, Pfizer, Integrated Diagnostics, and Philips.  

×

Let us help you do great proteomics!

Please click here to contact us.